Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 AbbViePfizerEli Lilly andMerck & Co., Inc.Novartis
SymbolNYSE:ABBVNYSE:PFENYSE:LLYNYSE:MRKNYSE:NVS
Price Information
Current Price$107.91$38.57$189.25$77.47$88.02
52 Week RangeBuyHoldBuyBuyHold
MarketRank™
Overall Score2.82.32.12.22.0
Analysis Score1.42.12.42.43.2
Community Score2.92.92.82.52.3
Dividend Score5.03.32.52.52.5
Ownership Score1.71.71.71.70.0
Earnings & Valuation Score3.11.31.31.91.9
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyHold
Consensus Price Target$115.75$38.57$196.40$96.27$108.50
% Upside from Price Target7.27% upside0.00% upside3.78% upside24.27% upside23.27% upside
Trade Information
Market Cap$190.44 billion$215.13 billion$181.49 billion$196.03 billion$201.45 billion
Beta0.840.70.370.430.59
Average Volume7,433,25232,094,1744,223,95511,803,3301,980,397
Sales & Book Value
Annual Revenue$33.27 billion$51.75 billion$22.32 billion$46.84 billion$47.50 billion
Price / Sales5.724.168.134.194.24
Cashflow$10.09 per share$4.30 per share$7.23 per share$6.29 per share$7.45 per share
Price / Cash10.708.9726.1912.3111.82
Book Value($5.53) per share$11.46 per share$2.81 per share$10.21 per share$24.53 per share
Price / Book-19.513.3767.357.593.59
Profitability
Net Income$7.88 billion$16.27 billion$8.32 billion$9.84 billion$11.73 billion
EPS$8.94$2.95$6.04$5.19$5.24
Trailing P/E Ratio22.8124.8830.9217.1428.49
Forward P/E Ratio8.8712.6023.7212.7613.50
P/E Growth1.542.791.571.891.76
Net Margins18.16%17.85%24.01%24.33%14.71%
Return on Equity (ROE)439.24%24.88%166.45%53.83%24.39%
Return on Assets (ROA)13.22%9.32%15.18%16.83%10.59%
Dividend
Annual Payout$5.20$1.56$3.40$2.60$2.08
Dividend Yield4.82%4.04%1.80%3.36%2.36%
Three-Year Dividend Growth84.37%-10.94%42.31%31.22%13.60%
Payout Ratio58.17%52.88%56.29%50.10%39.69%
Years of Consecutive Dividend Growth49 Years1 Years1 Years1 Years1 Years
Debt
Debt-to-Equity Ratio5.38%0.76%3.27%0.90%0.49%
Current Ratio0.95%1.40%1.36%1.30%0.91%
Quick Ratio0.81%1.13%1.06%1.00%0.69%
Ownership Information
Institutional Ownership Percentage67.49%67.36%75.59%72.86%9.86%
Insider Ownership Percentage0.09%0.08%0.09%0.28%0.01%
Miscellaneous
Employees47,00088,30035,00073,000105,794
Shares Outstanding1.76 billion5.58 billion958.99 million2.53 billion2.29 billion
Next Earnings Date4/30/2021 (Confirmed)5/4/2021 (Confirmed)4/27/2021 (Confirmed)4/29/2021 (Confirmed)4/27/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra - Yahoo FinanceNovartis (NVS) Collaborates with Roche for API of RA Drug Actemra - Yahoo Finance
finance.yahoo.com - April 16 at 6:53 PM
Novartis AG - Consensus Indicates Potential 20.7% Upside - DirectorsTalk InterviewsNovartis AG - Consensus Indicates Potential 20.7% Upside - DirectorsTalk Interviews
directorstalkinterviews.com - April 16 at 1:52 PM
Novartis : Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS - Marketscreener.comNovartis : Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS - Marketscreener.com
marketscreener.com - April 16 at 3:51 AM
June 18th Options Now Available For Novartis (NVS) - NasdaqJune 18th Options Now Available For Novartis (NVS) - Nasdaq
nasdaq.com - April 15 at 8:43 PM
Should You Accumulate Novartis AG (NVS) in Drug Manufacturers - General Industry? - InvestorsObserverShould You Accumulate Novartis AG (NVS) in Drug Manufacturers - General Industry? - InvestorsObserver
investorsobserver.com - April 15 at 3:42 PM
Hilton, Novartis among top 50 large workplaces - Canadian HR ReporterHilton, Novartis among top 50 large workplaces - Canadian HR Reporter
hrreporter.com - April 15 at 3:42 PM
Worldwide Generic Drugs Industry to 2026 - Players Include Mylan, Novartis and Pfizer Among Others - Yahoo FinanceWorldwide Generic Drugs Industry to 2026 - Players Include Mylan, Novartis and Pfizer Among Others - Yahoo Finance
finance.yahoo.com - April 15 at 10:26 AM
iRhythm Underplays Pervasive Consequences Of Novartis Code Changes - Seeking AlphaiRhythm Underplays Pervasive Consequences Of Novartis Code Changes - Seeking Alpha
seekingalpha.com - April 15 at 10:26 AM
Novartis: Seeking a Step Change in Global Health Outcomes - Pharmaceutical ExecutiveNovartis: Seeking a Step Change in Global Health Outcomes - Pharmaceutical Executive
pharmexec.com - April 15 at 10:26 AM
CureVac says it is on track with COVID-19 vaccine as it posts earnings updateCureVac says it is on track with COVID-19 vaccine as it posts earnings update
finance.yahoo.com - April 15 at 10:26 AM
Novartis agrees to make ingredients Roches Actemra for COVID-19 patients - WHBL NewsNovartis agrees to make ingredients Roche's Actemra for COVID-19 patients - WHBL News
whbl.com - April 15 at 5:25 AM
Gene therapies for neurodegenerative diseases: Pfizer, Novartis, Biogen and others seek more from FDA - Endpoints NewsGene therapies for neurodegenerative diseases: Pfizer, Novartis, Biogen and others seek more from FDA - Endpoints News
endpts.com - April 13 at 8:49 PM
FDA approves new self-injection administration for Xolair - PMLiVEFDA approves new self-injection administration for Xolair - PMLiVE
pmlive.com - April 13 at 3:49 PM
First Week of April 16th Options Trading For Novartis (NVS) - NasdaqFirst Week of April 16th Options Trading For Novartis (NVS) - Nasdaq
nasdaq.com - April 13 at 3:49 PM
Genentech and Novartis Win FDA Approval for Self-Injectable Form of Xolair - BioSpaceGenentech and Novartis Win FDA Approval for Self-Injectable Form of Xolair - BioSpace
biospace.com - April 13 at 3:49 PM
Novartis in Canada named a Top 50 Best Workplace™ in the country - Yahoo FinanceNovartis in Canada named a Top 50 Best Workplace™ in the country - Yahoo Finance
finance.yahoo.com - April 13 at 3:49 PM
NVS Named Top 10 SAFE International Dividend StockNVS Named Top 10 SAFE International Dividend Stock
nasdaq.com - April 13 at 9:19 AM
Delhi HC Restrains Eris Lifesciences from Infringing Novartis Sacubitril, Valsartan FDC - Medical DialoguesDelhi HC Restrains Eris Lifesciences from Infringing Novartis Sacubitril, Valsartan FDC - Medical Dialogues
medicaldialogues.in - April 12 at 5:57 PM
AACR: BeiGene details Novartis-partnered PD-1s first global pivotal win in lung cancer. Should Opdivo maker BMS be concerned? - FiercePharmaAACR: BeiGene details Novartis-partnered PD-1's first global pivotal win in lung cancer. Should Opdivo maker BMS be concerned? - FiercePharma
fiercepharma.com - April 12 at 5:57 PM
Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients - PRNewswireNovartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients - PRNewswire
prnewswire.com - April 12 at 5:57 PM
Novartis wins injunction to stop generic version of blockbuster MS drug, for now - LawyerlyNovartis wins injunction to stop generic version of blockbuster MS drug, for now - Lawyerly
lawyerly.com.au - April 12 at 7:56 AM
Insights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - PRNewswireInsights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - PRNewswire
prnewswire.com - April 9 at 9:59 PM
Insights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - Yahoo FinanceInsights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - Yahoo Finance
finance.yahoo.com - April 9 at 4:58 PM
Regeneron Pharmaceuticals : Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission - Marketscreener.comRegeneron Pharmaceuticals : Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission - Marketscreener.com
marketscreener.com - April 9 at 4:58 PM
NOVARTIS AG : Receives a Sell rating from JP Morgan - marketscreener.comNOVARTIS AG : Receives a Sell rating from JP Morgan - marketscreener.com
marketscreener.com - April 9 at 6:57 AM
DateCompanyBrokerageAction
4/7/2021AbbVieRoyal Bank of CanadaInitiated Coverage
3/30/2021AbbVieSVB LeerinkBoost Price Target
2/4/2021AbbVieMizuhoBoost Price Target
1/28/2021AbbVieMorgan StanleyLower Price Target
11/18/2020AbbVieBMO Capital MarketsInitiated Coverage
11/10/2020AbbVieSanford C. BernsteinInitiated Coverage
10/23/2020AbbVieTruistInitiated Coverage
10/20/2020AbbVieThe Goldman Sachs GroupDowngrade
10/16/2020AbbVieJPMorgan Chase & Co.Boost Price Target
9/29/2020AbbVieBerenberg BankInitiated Coverage
9/2/2020AbbVieCitigroupBoost Price Target
6/23/2020AbbVieAtlantic SecuritiesUpgrade
2/3/2021PfizerDZ BankReiterated Rating
12/4/2020PfizerBarclaysBoost Price Target
3/22/2021Eli Lilly andTruist SecuritiesBoost Price Target
2/12/2021Eli Lilly andCowenBoost Price Target
1/22/2021Eli Lilly andBank of AmericaBoost Price Target
12/10/2020Eli Lilly andWolfe ResearchUpgrade
6/16/2020Eli Lilly andGuggenheimUpgrade
2/5/2021Merck & Co., Inc.Cantor FitzgeraldReiterated Rating
5/4/2020Merck & Co., Inc.Credit Suisse GroupReiterated Rating
4/13/2020Merck & Co., Inc.UBS GroupLower Price Target
3/24/2020Merck & Co., Inc.ArgusLower Price Target
3/23/2021NovartisSociete GeneraleReiterated Rating
1/15/2021NovartisDeutsche Bank AktiengesellschaftInitiated Coverage
9/23/2020NovartisOddo BhfDowngrade
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.